Zackrisson B, Gustafsson H, Stenling R, Flygare P, Wilson G D
Department of Oncology, Umeå University, Sweden.
Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):677-83. doi: 10.1016/s0360-3016(97)00066-7.
The goal of this study was to investigate the clinical utility of pretreatment measurements of tumor cell kinetics to predict the outcome of patients with squamous cell carcinoma of the head and neck receiving conventional radiotherapy.
All patients received between 64 and 70 Gy as 2 Gy fractions, five fractions per week. Cell kinetics were assayed rapidly and quantitatively using flow cytometric evaluation of iododeoxyuridine (IdUrd) incorporation, in vivo, from a biopsy removed several hours after the administration of the DNA precursor to the patient prior to the start of treatment.
The measured proliferation parameters were not related to the clinicopathological features of the tumors, emphasizing the independent nature of these parameters. In univariate analysis, nodal involvement was the most important clinical feature of the tumors related to local control followed by Tpot, DNA aneuploidy, and attainment of complete regression at 6 weeks. Of these only Tpot and nodal status maintained significance in multivariate analysis, with respect to loco-regional control. In subgroup analysis, Tpot was able to stratify patients into high or low rate of loco-regional control in node negative patients, in aneuploid tumors and in patients who did achieve complete regression at 6 weeks. For cause specific survival, N-stage was the only parameter that significantly discriminated the prognosis in these patients.
The conclusion of this study is that Tpot provides clinically important information that can predict patients with a low probability of achieving long-term local control with conventional fractionation. Further improvements to the methodology to address the shortcomings of analyzing diploid tumors may increase the predictive power of the measurement.
本研究的目的是探讨肿瘤细胞动力学预处理测量对预测接受常规放疗的头颈部鳞状细胞癌患者预后的临床实用性。
所有患者接受64至70 Gy的放疗,每次分割剂量为2 Gy,每周5次。在治疗开始前,给患者注射DNA前体数小时后,从活检组织中快速、定量地检测细胞动力学,采用流式细胞术评估碘脱氧尿苷(IdUrd)的体内掺入情况。
所测量的增殖参数与肿瘤的临床病理特征无关,强调了这些参数的独立性。在单因素分析中,淋巴结受累是与局部控制相关的肿瘤最重要的临床特征,其次是Tpot、DNA非整倍体以及6周时达到完全缓解。在多因素分析中,就局部区域控制而言,只有Tpot和淋巴结状态保持显著意义。在亚组分析中,Tpot能够将淋巴结阴性患者、非整倍体肿瘤患者以及6周时确实达到完全缓解的患者分层为局部区域控制率高或低的患者。对于特定病因生存率,N分期是唯一能显著区分这些患者预后的参数。
本研究的结论是,Tpot提供了重要的临床信息,可预测采用常规分割放疗实现长期局部控制可能性低的患者。针对分析二倍体肿瘤缺点的方法学进一步改进可能会提高测量的预测能力。